Caplin point laboratories has received final approval from the United States Food and Drug Administration (USFDA) for Potassium Phosphates Injection USP through its subsidiary, Caplin Steriles Limited. The approval was announced in a regulatory filing under Regulation 30, marking a significant milestone for the pharmaceutical company's US market expansion.

Product Details and Market Opportunity

The USFDA granted approval for the Abbreviated New Drug Application (ANDA) for Potassium Phosphates Injection USP, containing phosphorus 3 mmol/mL and potassium 4.4 mEq/mL in 5 mL, 15 mL and 50 mL vials. This generic version serves as a therapeutic equivalent to the Reference Listed Drug from Fresenius Kabi USA, LLC.

According to IQVIA data, the product recorded US sales of approximately $57 million for the 12-month period ending January 2026, indicating substantial commercial potential in this therapeutic segment.

Therapeutic Applications

Potassium Phosphates Injection is used as a source of phosphorus in intravenous fluids to correct hypophosphatemia and as parenteral nutrition in adults and pediatric patients who cannot take oral supplements. This positions the product in the critical care and hospital segment of the pharmaceutical market.

Strategic Significance

This regulatory milestone strengthens Caplin Point Laboratories' position in the US pharmaceutical market, particularly in the sterile injectables segment. Caplin Steriles Limited has developed and filed 54 ANDAs in the USA, achieving 53 approvals including acquired ANDAs. The subsidiary maintains approvals from multiple regulatory agencies including US FDA, EU-GMP, ANVISA and INVIMA.

The company is working on a portfolio of 55+ simple and complex injectable and ophthalmic products intended for filing over the next four years, demonstrating its commitment to expanding its US market presence.

Caplin Point Laboratories Limited has informed stock exchanges about the cessation of Dr. C K Gariyali as an Independent Director, effective from the close of business hours on March 03, 2026. The announcement was made in compliance with Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Board Change Details

The cessation follows the completion of Dr. Gariyali's maximum permitted tenure as an Independent Director. According to the company's disclosure, she had served her second term as an Independent Director and ceased her role in accordance with the terms of her appointment.

Regulatory Compliance

Caplin Point Laboratories has filed the requisite disclosure with both BSE Limited and National Stock Exchange of India Ltd. The communication was signed by Venkatram G, General Counsel & Company Secretary (Membership No. A23989), ensuring proper compliance with regulatory requirements.

Corporate Governance Framework

The cessation aligns with corporate governance norms that limit the tenure of Independent Directors to ensure board independence and fresh perspectives. The company has followed due process in accordance with SEBI Master circular HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026.

The pharmaceutical company continues to maintain its commitment to regulatory compliance and transparent disclosure practices through timely communication with stakeholders and stock exchanges.